Company_NN Information_NN 141_CD ACCOUNTING_NNP POLICIES_NNP Basis_NN of_IN accounting_NN The_DT Financial_NNP Statements_NNP are_VBP prepared_VBN under_IN the_DT historical_JJ cost_NN convention_NN ,_, modified_VBN to_TO include_VB revaluation_NN to_TO fair_JJ value_NN of_IN certain_JJ financial_JJ instruments_NNS as_IN described_VBN below_IN ,_, in_IN accordance_NN with_IN the_DT Companies_NNS Act_NNP 1985_CD and_CC UK_NNP Generally_RB Accepted_JJ Accounting_NN Principles_NNPS UK_NNP GAAP_NNP ._.
The_DT following_VBG paragraphs_NNS describe_VBP the_DT main_JJ accounting_NN policies_NNS under_IN UK_NNP GAAP_NNP ,_, which_WDT have_VBP been_VBN applied_VBN consistently_RB ._.
New_NNP Accounting_NNP Standards_NNPS The_DT Company_NN has_VBZ adopted_VBN the_DT following_JJ accounting_NN standards_NNS in_IN the_DT year_NN :_: Financial_NNP Reporting_NNP Standard_NNP No._NN ._.
Under_IN FRS_NNP 20_CD ,_, the_DT Company_NN is_VBZ required_VBN to_TO reflect_VB share-based_JJ payments_NNS in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
In_IN the_DT Companys_NNPS case_NN ,_, share-based_JJ payments_NNS comprise_VBP primarily_RB share_NN options_NNS through_IN the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Scheme_NN and_CC the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN ._.
The_DT provisions_NNS of_IN FRS_NNP 20_CD have_VBP been_VBN applied_VBN to_TO options_NNS granted_VBN after_IN 7_CD November_NNP 2002_CD ._.
The_DT adoption_NN of_IN FRS_NNP 20_CD had_VBD no_DT effect_NN on_IN the_DT Companys_NNP profit_NN or_CC net_JJ assets_NNS ._.
21Events_NNS after_IN the_DT Balance_NNP Sheet_NNP Date_NNP FRS_NNP 21_CD ._.
The_DT major_JJ effect_NN of_IN FRS_NNP 21_CD is_VBZ to_TO change_VB the_DT approach_NN to_TO dividends_NNS declared_VBN after_IN the_DT balance_NN sheet_NN date_NN in_IN respect_NN of_IN the_DT year_NN under_IN review_NN such_JJ that_IN these_DT dividends_NNS are_VBP no_RB longer_RB accrued_VBN for_IN in_IN the_DT balance_NN sheet_NN ._.
As_IN a_DT result_NN of_IN adopting_VBG FRS_NNP 21_CD ,_, the_DT Companys_NNPS net_JJ assets_NNS at_IN 31_CD December_NNP 2004_CD increased_VBN by_IN $_$ 1,061_CD m._FW 23The_NNP Effects_NNPS of_IN Changes_NNS in_IN Foreign_NNP Exchange_NNP Rates_NNP FRS_NNP 23_CD ._.
FRS_NNP 23_CD sets_VBZ out_RP additional_JJ guidance_NN on_IN the_DT translation_NN method_NN for_IN transactions_NNS in_IN foreign_JJ currencies_NNS and_CC on_IN determining_VBG the_DT functional_JJ and_CC presentation_NN currencies_NNS ._.
The_DT adoption_NN of_IN FRS_NNP 23_CD had_VBD no_DT effect_NN on_IN the_DT Companys_NNP profit_NN or_CC net_JJ assets_NNS ._.
25Financial_JJ Instruments_NNPS :_: Disclosure_NN and_CC Presentation_NN FRS_NNP 25_CD ._.
FRS_NNP 25_CD sets_VBZ out_RP the_DT requirements_NNS for_IN the_DT presentation_NN of_IN ,_, and_CC disclosures_NNS relating_VBG to_TO ,_, financial_JJ instruments_NNS ._.
The_DT adoption_NN of_IN FRS_NNP 25_CD had_VBD no_DT effect_NN on_IN the_DT Companys_NNP profit_NN or_CC net_JJ assets_NNS :_: disclosures_NNS complying_VBG with_IN the_DT requirements_NNS of_IN FRS_NNP 25_CD are_VBP included_VBN in_IN the_DT Financial_NNP Statements_NNP ._.
FRS_NNP 26_CD sets_VBZ out_RP requirements_NNS for_IN measurement_NN ,_, recognition_NN and_CC derecognition_NN of_IN financial_JJ instruments_NNS ._.
The_DT adoption_NN of_IN FRS_NNP 26_CD had_VBD no_DT effect_NN on_IN the_DT Companys_NNP profit_NN or_CC net_JJ assets_NNS ._.
FRS_NNP 28_CD sets_VBZ out_RP the_DT requirements_NNS for_IN the_DT disclosure_NN of_IN corresponding_JJ amounts_NNS for_IN items_NNS shown_VBN in_IN an_DT entitys_NNS primary_JJ financial_JJ statements_NNS and_CC the_DT notes_NNS to_TO the_DT financial_JJ statements_NNS ._.
The_DT adoption_NN of_IN FRS_NNP 28_CD had_VBD no_DT effect_NN upon_IN the_DT Companys_NNP profit_NN or_CC net_JJ assets_NNS ._.
Foreign_NNP currencies_NNS Profit_NN and_CC loss_NN accounts_NNS in_IN foreign_JJ currencies_NNS are_VBP translated_VBN into_IN US_NNP dollars_NNS at_IN average_JJ rates_NNS for_IN the_DT relevant_JJ accounting_NN periods_NNS ._.
Assets_NNS and_CC liabilities_NNS are_VBP translated_VBN at_IN exchange_NN rates_NNS prevailing_VBG at_IN the_DT date_NN of_IN the_DT Company_NN balance_NN sheet_NN ._.
Exchange_NNP gains_NNS and_CC losses_NNS are_VBP included_VBN within_IN net_JJ interest_NN payable_JJ ._.
Taxation_NNP The_NNP charge_NN for_IN taxation_NN is_VBZ based_VBN on_IN the_DT result_NN for_IN the_DT year_NN and_CC takes_VBZ into_IN account_NN taxation_NN deferred_VBN because_IN of_IN timing_NN differences_NNS between_IN the_DT treatment_NN of_IN certain_JJ items_NNS for_IN taxation_NN and_CC for_IN accounting_NN purposes_NNS ._.
Full_JJ provision_NN is_VBZ made_VBN for_IN the_DT effects_NNS of_IN these_DT differences_NNS ._.
Deferred_JJ tax_NN asset_NN valuation_NN allowances_NNS are_VBP made_VBN where_WRB it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB that_IN the_DT asset_NN will_MD not_RB be_VB realized_VBN in_IN the_DT future_NN ._.
These_DT valuations_NNS require_VBP judgements_NNS to_TO be_VB made_VBN including_VBG the_DT forecast_NN of_IN future_JJ taxable_JJ income_NN ._.
Deferred_JJ tax_NN balances_NNS are_VBP not_RB discounted_VBN ._.
Accruals_NNS for_IN tax_NN contingencies_NNS require_VBP management_NN to_TO make_VB judgements_NNS and_CC estimates_NNS in_IN relation_NN to_TO tax_NN audit_NN issues_NNS ._.
Tax_NNP benefits_NNS are_VBP not_RB recognized_VBN unless_IN the_DT tax_NN positions_NNS will_MD probably_RB be_VB sustained_VBN ._.
Once_RB considered_VBN to_TO be_VB probable_JJ ,_, management_NN reviews_NNS each_DT material_NN tax_NN benefit_NN to_TO assess_VB whether_IN a_DT provision_NN should_MD be_VB taken_VBN against_IN full_JJ recognition_NN of_IN that_DT benefit_NN on_IN the_DT basis_NN of_IN potential_JJ settlement_NN through_IN negotiation_NN and_CC or_CC litigation_NN ._.
Any_DT recorded_VBN exposure_NN to_TO interest_NN on_IN tax_NN liabilities_NNS is_VBZ provided_VBN for_IN in_IN the_DT tax_NN charge_NN ._.
All_DT provisions_NNS are_VBP included_VBN in_IN creditors_NNS due_JJ within_IN one_CD year_NN ._.
Investments_NNP Fixed_NNP asset_NN investments_NNS ,_, including_VBG investments_NNS in_IN subsidiaries_NNS ,_, are_VBP stated_VBN at_IN cost_NN and_CC reviewed_VBN for_IN impairment_NN if_IN there_EX are_VBP indications_NNS that_IN the_DT carrying_VBG value_NN may_MD not_RB be_VB recoverable_JJ ._.
Financial_NNP instruments_NNS Loans_NNS and_CC receivables_NNS are_VBP held_VBN at_IN amortised_JJ cost_NN ._.
Long_JJ term_NN loans_NNS payable_JJ are_VBP held_VBN at_IN amortised_JJ cost_NN ._.
Other_JJ financial_JJ instruments_NNS ,_, including_VBG derivatives_NNS ,_, are_VBP held_VBN at_IN fair_JJ value_NN :_: changes_NNS in_IN fair_JJ value_NN are_VBP reflected_VBN in_IN the_DT income_NN statement_NN ._.
Contingent_JJ liabilities_NNS Through_IN the_DT normal_JJ course_NN of_IN business_NN ,_, AstraZeneca_NNP is_VBZ involved_VBN in_IN legal_JJ disputes_NNS ,_, the_DT settlement_NN of_IN which_WDT may_MD involve_VB cost_NN to_TO the_DT Company_NN ._.
Provision_NNP is_VBZ made_VBN where_WRB an_DT adverse_JJ outcome_NN is_VBZ probable_JJ and_CC associated_VBN costs_NNS can_MD be_VB estimated_VBN reliably_RB ._.
